Endocare: Cryoablation studies demonstrate effectiveness in treating kidney cancer

By E. Janene Geiss

Philadelphia, July 26 - Endocare, Inc. said Wednesday that six studies and papers demonstrating the effectiveness of cryoablation for treating kidney, or renal, cancer show that renal cryoablation is a less invasive treatment than standard surgery and generally results in less morbidity, faster recovery and fewer complications.

Renal cryoablation involves freezing and destroying the diseased tissue using an Endocare cryoablation device, officials said in a company news release.

Standard surgery generally involved full or partial removal of the affected kidney.

The six studies, which included 379 patients and comparisons between cryoablation and other ablative treatments, show that cryoablation can be a safe and effective treatment for renal cancer with few serious complications and can be repeated if the disease reoccurs, officials said.

In one of the studies, 48 patients who received the procedure had a cancer specific survival rate of 100% and no major complications, officials said.

Persistent disease was noted in six of the patients, or 12.5%, officials said.

After a repeat procedure, five of the six now show no evidence of disease yielding a 97.5% cancer-free survival rate for all patients in the study, officials said.

Results of these studies were published in a supplement to the July 2006 Urology journal.

Endocare is an Irvine, Calif., medical device company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.